Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024

Marine Maurel, Jennifer Howard, Esther Kissling,Francisco Pozo,Gloria Perez-Gimeno,Silke Buda, Noemie Seve, Adele McK-enna,Adam Meijer,Ana Paula Rodrigues,Ivan Martinez-Baz, Ivan Mlinaric,Neus Latorre-Margalef,Gergo Turi, Mihaela Lazar,Clara Mazagatos,Aitziber Echeverria, Stephen Abela,Marc Bourgeois,Ausenda Machado,Ralf Duerrwald,Goranka Petrovic,Beatrix Oroszi,Ligita Jancoriene, Alexandru Marin,Petr Husa, Roisin Duffy,Frederika Dijkstra, Virtudes Gallardo Garcia,Luise Goerlitz,Vincent Enouf,Charlene Bennett,Mariette Hooiveld, Raquel Guiomar,Camino Trobajo-Sanmartin,Vesna Visekruna Vucina, Tove Samuelsson Hagey, Ana Sofia Lameiras Azevedo,Jesus Castilla, Gerd Xuereb,Benedicte Delaere,Veronica Gomez,Kristin Tolksdorf,Sabrina Bacci,Nathalie Nicolay, Marlena Kaczmarek, Angela MC Rose

EUROSURVEILLANCE（2024）

引用 0|浏览3

暂无评分

摘要

Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU -PC) and hospital (EU -H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU -PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU -H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), respectively.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要